Introduction: Aminoglycosides used for treating multidrug-resistant (MDR) tuberculosis are ototoxic, leading to a need for audiological monitoring. While audiologists monitor ototoxicity, currently there are no guidelines on monitoring in the South African context. Therefore, the findings of this study might help to motivate the establishment of a more in-depth ototoxicity monitoring policy, which facilitates uniformity among audiologists managing patients with MDR tuberculosis. Therefore, the study aimed to describe the audiological practices employed by audiologists in the management of adult patients with MDR tuberculosis in South Africa.Method: A descriptive survey design was used. A questionnaire was developed and included elements of ...
Problem Statement Individuals treated for multidrug-resistant tuberculosis (MDR-TB) with aminoglycos...
Magister Public Health - MPHOtotoxic induced hearing loss is a common adverse event related to amino...
BACKGROUND: Amikacin and kanamycin are mainly used for treating multidrug-resistant tuberculosis (MD...
In response to the drug-resistant tuberculosis (DRTB) ototoxicity burden in South Africa, ototoxici...
Multi-drug resistance is increasingly becoming a challenge to tuberculosis control programmes global...
In response to the drug-resistant tuberculosis (DRTB) ototoxicity burden in South Africa, ototoxicit...
Background: South Africa is a high-burden multi-drug-resistant tuberculosis (MDR-TB) country. Previo...
Abstract INTRODUCTION: A total of 771 cases of multidrug-resistant tuberculosis (MDR-TB) were repo...
BACKGROUND: Multidrug-resistant tuberculosis (MDR TB) is a disease condition of TB that resistant to...
The purpose of the study was to develop best practice guidelines to prevent permanent hearing loss a...
Background: The recommended treatment of MDR TB lasts for 20 months following therapy with second li...
Background: Ototoxicity is damage to cells in the inner ear after administering a toxic drug, with a...
ABSTRACTS:BACKGROUND: To investigate the Cochleo-vestibular clinical and audiometric findings in Mul...
The treatment of drug-resistant (DR)-tuberculosis (TB) necessitates the use of second-line injectabl...
PURPOSE: To evaluate the association between the use of streptomycin, amikacin, kanamycin and capreo...
Problem Statement Individuals treated for multidrug-resistant tuberculosis (MDR-TB) with aminoglycos...
Magister Public Health - MPHOtotoxic induced hearing loss is a common adverse event related to amino...
BACKGROUND: Amikacin and kanamycin are mainly used for treating multidrug-resistant tuberculosis (MD...
In response to the drug-resistant tuberculosis (DRTB) ototoxicity burden in South Africa, ototoxici...
Multi-drug resistance is increasingly becoming a challenge to tuberculosis control programmes global...
In response to the drug-resistant tuberculosis (DRTB) ototoxicity burden in South Africa, ototoxicit...
Background: South Africa is a high-burden multi-drug-resistant tuberculosis (MDR-TB) country. Previo...
Abstract INTRODUCTION: A total of 771 cases of multidrug-resistant tuberculosis (MDR-TB) were repo...
BACKGROUND: Multidrug-resistant tuberculosis (MDR TB) is a disease condition of TB that resistant to...
The purpose of the study was to develop best practice guidelines to prevent permanent hearing loss a...
Background: The recommended treatment of MDR TB lasts for 20 months following therapy with second li...
Background: Ototoxicity is damage to cells in the inner ear after administering a toxic drug, with a...
ABSTRACTS:BACKGROUND: To investigate the Cochleo-vestibular clinical and audiometric findings in Mul...
The treatment of drug-resistant (DR)-tuberculosis (TB) necessitates the use of second-line injectabl...
PURPOSE: To evaluate the association between the use of streptomycin, amikacin, kanamycin and capreo...
Problem Statement Individuals treated for multidrug-resistant tuberculosis (MDR-TB) with aminoglycos...
Magister Public Health - MPHOtotoxic induced hearing loss is a common adverse event related to amino...
BACKGROUND: Amikacin and kanamycin are mainly used for treating multidrug-resistant tuberculosis (MD...